Literature DB >> 3086724

Drug therapy. Tocainide.

D M Roden, R L Woosley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086724     DOI: 10.1056/NEJM198607033150107

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 2.  Stopping and restarting medications in the perioperative period.

Authors:  R Cygan; H Waitzkin
Journal:  J Gen Intern Med       Date:  1987 Jul-Aug       Impact factor: 5.128

3.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

Authors:  S Talon; A De Luca; M De Bellis; J F Desaphy; G Lentini; A Scilimati; F Corbo; C Franchini; P Tortorella; H Jockusch; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Arrhythmias: antiarrhythmic agents.

Authors:  R J Herman
Journal:  Can Fam Physician       Date:  1987-04       Impact factor: 3.275

Review 5.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 6.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.